FEM-UP
Main information
- Trade name:
- FEM-UP 200ML SYR
- Available from:
- Shinto Org.
- Pharmaceutical form:
- SYR
- Composition:
- 200ML
- Medicine domain:
- Humans
- Medicine type:
- Allopathic drug
Documents
- for the general public:
- The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.
Request the information leaflet for the general public.
- for healthcare professionals:
- The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.
Request the information leaflet for healthcare professionals.
Localization
- Available in:
-
India
- Language:
- English
Other information
Status
- Source:
- Central Drugs Standard Control Organization
- Last update:
- 09-08-2016
- The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.
Request the information leaflet for the general public.
- Access to this document is only available to registered users.
Register now for full access
15-8-2018
G Female Oral Tablets
G Female Oral Tablets pose a serious risk to your health and should not be taken
Therapeutic Goods Administration - Australia
19-7-2018
Assessment of the safety of feminine hygiene products
Today ANSES is publishing its health risk assessment on the safety of feminine hygiene products. Chemicals have been identified in these products at very low concentrations not exceeding health thresholds. The expert appraisal did not reveal any risk associated with these substances. Nevertheless, the Agency recommends that manufacturers improve the quality of these products in order to eliminate or minimise the presence of chemicals. ANSES’s expert appraisal also examined the risk of menstrual toxic sho...
France - Agence Nationale du Médicament Vétérinaire
31-5-2018
LFIT Anatomic CoCr V40 Femoral Heads
Hazard alert - potential for components to separate
Therapeutic Goods Administration - Australia
15-10-2018
We have created a rumor control page for Hurricane #Michael that will be updated regularly. Help us share this info and remember to always check with official sources like @FLSERT, @GeorgiaEMA and @femaregion4. http://fema.gov/hurricane-michael-rumor-co
We have created a rumor control page for Hurricane #Michael that will be updated regularly. Help us share this info and remember to always check with official sources like @FLSERT, @GeorgiaEMA and @femaregion4. http://fema.gov/hurricane-michael-rumor-control … pic.twitter.com/T3h7ZiFUrZ
FDA - U.S. Food and Drug Administration
26-9-2018
The single-use internal condom (formerly the single-use female condom) is the only female-controlled barrier method intended to provide protection against pregnancy & STI transmission. Check out the FDA's birth control guide: https://go.usa.gov/xPDQw #M
The single-use internal condom (formerly the single-use female condom) is the only female-controlled barrier method intended to provide protection against pregnancy & STI transmission. Check out the FDA's birth control guide: https://go.usa.gov/xPDQw #MedicalDevices
FDA - U.S. Food and Drug Administration
19-9-2018
If your home was damaged or if you had flood loss due to #Florence, start the recovery process by filing your homeowner’s and flood insurance claims. Insurance is the most effective tool for recovery. More on filing a flood insurance claim: http://fema.
If your home was damaged or if you had flood loss due to #Florence, start the recovery process by filing your homeowner’s and flood insurance claims. Insurance is the most effective tool for recovery. More on filing a flood insurance claim: http://fema.gov/nfip-file-your-claim … pic.twitter.com/lv5Na8Zw8c
FDA - U.S. Food and Drug Administration
22-7-2018
We must address data gaps on tech for women’s health. Our new Women’s Health Technologies Strategically Coordinated Registry Network https://bit.ly/2L4Tqsx provides more evidence on areas as uterine fibroids, pelvic floor disorders & female long-acting
We must address data gaps on tech for women’s health. Our new Women’s Health Technologies Strategically Coordinated Registry Network https://bit.ly/2L4Tqsx provides more evidence on areas as uterine fibroids, pelvic floor disorders & female long-acting reversible contraception pic.twitter.com/TAWmVh99oL
FDA - U.S. Food and Drug Administration